Literature DB >> 9049541

Pharmacological differences between calcium antagonists.

L H Opie1.   

Abstract

The calcium channel antagonists are not an homogeneous group. From both pharmacological and clinical points of view, they can be divided into those of the dihydropyridine family like nifedipine, and those of the non-dihydropyridine family like verapamil and diltiazem. These families bind at different sites to the calcium channel, which may explain some of the clinical differences. The dihydropyridines are more vascular selective and the non-dihydropyridines are more myocardial selective and tend to reduce the heart rate. Further important differences are between short- and long-acting forms of the calcium channel antagonists. From the clinical point of view, these agents are most used in angina pectoris and hypertension. Emerging studies suggest that in angina of effort these agents have a safety record somewhat similar to that of beta-blockers. In congestive heart failure, these agents, as a group, are contraindicated.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9049541     DOI: 10.1093/eurheartj/18.suppl_a.71

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  9 in total

1.  Calcium channel blockers are inadequate for malignant hyperthermia crisis.

Authors:  Takako Migita; Keiko Mukaida; Toshimichi Yasuda; Hiroshi Hamada; Masashi Kawamoto
Journal:  J Anesth       Date:  2012-02-16       Impact factor: 2.078

2.  Smooth muscle contractility causes the gut to grow anisotropically.

Authors:  Diana Khalipina; Yusuke Kaga; Nicolas Dacher; Nicolas R Chevalier
Journal:  J R Soc Interface       Date:  2019-10-09       Impact factor: 4.118

3.  Identifying the Transcriptome Signatures of Calcium Channel Blockers in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

Authors:  Chi Keung Lam; Lei Tian; Nadjet Belbachir; Alexa Wnorowski; Rajani Shrestha; Ning Ma; Tomoya Kitani; June-Wha Rhee; Joseph C Wu
Journal:  Circ Res       Date:  2019-05-13       Impact factor: 17.367

4.  Replacement of Amlodipine and Lercanidipine by Barnidipine: Tolerability and Effectiveness in a Real-Life Study.

Authors:  Robert Lins; Yves Haerden; Caroline de Vries
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-03

Review 5.  Olmesartan/amlodipine: a review of its use in the management of hypertension.

Authors:  R Kreutz
Journal:  Vasc Health Risk Manag       Date:  2011-03-29

6.  Aging Reduces L-Type Calcium Channel Current and the Vasodilatory Response of Small Mesenteric Arteries to Calcium Channel Blockers.

Authors:  Sulayma A Albarwani; Fathi Mansour; Abdul Aleem Khan; Intisar Al-Lawati; Abdulla Al-Kaabi; Al-Manar Al-Busaidi; Safa Al-Hadhrami; Isehaq Al-Husseini; Sultan Al-Siyabi; Musbah O Tanira
Journal:  Front Physiol       Date:  2016-05-20       Impact factor: 4.566

7.  Verapamil Inhibits TRESK (K2P18.1) Current in Trigeminal Ganglion Neurons Independently of the Blockade of Ca2+ Influx.

Authors:  Hyun Park; Eun-Jin Kim; Ji Hyeon Ryu; Dong Kun Lee; Seong-Geun Hong; Jaehee Han; Jongwoo Han; Dawon Kang
Journal:  Int J Mol Sci       Date:  2018-07-04       Impact factor: 5.923

Review 8.  Management of Blood Pressure During and After Recanalization Therapy for Acute Ischemic Stroke.

Authors:  Jeffrey R Vitt; Michael Trillanes; J Claude Hemphill
Journal:  Front Neurol       Date:  2019-02-21       Impact factor: 4.003

9.  Selective uveal melanoma inhibition with calcium channel blockade.

Authors:  Michael Shaughnessy; Grace Lamuraglia; Nikolai Klebanov; Zhenyu Ji; Anpuchchelvi Rajadurai; Raj Kumar; Keith Flaherty; Hensin Tsao
Journal:  Int J Oncol       Date:  2019-09-06       Impact factor: 5.650

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.